



Pre - PA Allowance

None

Prior-Approval Requirements

Age 12 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Metastatic Merkel cell carcinoma (MCC)
2. Locally advanced or metastatic urothelial carcinoma with **ONE** of the following:
 - a. **NO** disease progression with first-line platinum-containing chemotherapy
 - a. Used as maintenance treatment
 - b. Disease progression during or following platinum-containing chemotherapy
 - c. Disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
3. Advanced renal cell carcinoma (RCC)
 - a. Used in combination with Inlyta (axitinib)
 - b. First-line treatment
 - c. Liver enzymes will be monitored
 - d. Patient will be monitored for cardiovascular events

AND ALL of the following:

- a. Prescriber agrees to monitor for all immune-mediated adverse reactions and discontinue therapy if necessary
- b. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during therapy and for at least 1 month after the last dose

Prior - Approval Limits

Duration 12 months



Prior – Approval *Renewal* Requirements

Age 12 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Metastatic Merkel cell carcinoma (MCC)
2. Locally advanced or metastatic urothelial carcinoma
3. Advanced renal cell carcinoma (RCC)
 - a. Used in combination with Inlyta (axitinib)
 - b. Liver enzymes will be monitored
 - c. Patient will be monitored for cardiovascular events

AND ALL of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor for all immune-mediated adverse reactions and discontinue therapy if necessary
- c. Female patients of reproductive potential only: patient will be advised to use effective contraception during therapy and for at least 1 month after the last dose

Prior - Approval *Renewal* Limits

Same as above